Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.

Autor: Marks JD; Medical Scientist Training Program, Mayo Clinic Alix School of Medicine, Rochester, MN, USA., Syrjanen JA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Graff-Radford J; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Petersen RC; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Machulda MM; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA., Campbell MR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Algeciras-Schimnich A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Lowe V; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Knopman DS; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Jack CR Jr; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Vemuri P; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Mielke MM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. Mielke.Michelle@mayo.edu.; Department of Neurology, Mayo Clinic, Rochester, MN, USA. Mielke.Michelle@mayo.edu.
Jazyk: angličtina
Zdroj: Alzheimer's research & therapy [Alzheimers Res Ther] 2021 Dec 14; Vol. 13 (1), pp. 199. Date of Electronic Publication: 2021 Dec 14.
DOI: 10.1186/s13195-021-00944-y
Abstrakt: Background: Total tau protein (T-Tau) and neurofilament light chain (NfL) have emerged as candidate plasma biomarkers of neurodegeneration, but studies have not compared how these biomarkers cross-sectionally or longitudinally associate with cognitive and neuroimaging measures. We therefore compared plasma T-Tau and NfL as cross-sectional and longitudinal markers of (1) global and domain-specific cognitive decline and (2) neuroimaging markers of cortical thickness, hippocampal volume, white matter integrity, and white matter hyperintensity volume.
Methods: We included 995 participants without dementia who were enrolled in the Mayo Clinic Study of Aging cohort. All had concurrent plasma NfL and T-tau, cognitive status, and neuroimaging data. Follow-up was repeated approximately every 15 months for a median of 6.2 years. Plasma NfL and T-tau were measured on the Simoa-HD1 Platform. Linear mixed effects models adjusted for age, sex, and education examined associations between baseline z-scored plasma NfL or T-tau and cognitive or neuroimaging outcomes. Analyses were replicated in Alzheimer's Disease Neuroimaging Initiative (ADNI) among 387 participants without dementia followed for a median of 3.0 years.
Results: At baseline, plasma NfL was more strongly associated with all cognitive and neuroimaging outcomes. The combination of having both elevated NfL and T-tau at baseline, compared to elevated levels of either alone, was more strongly associated at cross-section with worse global cognition and memory, and with neuroimaging measures including temporal cortex thickness and increased number of infarcts. In longitudinal analyses, baseline plasma T-tau did not add to the prognostic value of baseline plasma NfL. Results using ADNI data were similar.
Conclusions: Our results indicate plasma NfL had better utility as a prognostic marker of cognitive decline and neuroimaging changes. Plasma T-tau added cross-sectional value to NfL in specific contexts.
Trial Registration: Not applicable.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje